Press release
Eton Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE®
- Tolmar’s 62-person sales force will co-promote ALKINDI SPRINKLE® to pediatric endocrinologists - DEER PARK, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Eton
About this update from Eton Pharmaceuticals, Inc.
[{"type":"text","content":"- Tolmar’s 62-person sales force will co-promote ALKINDI SPRINKLE® to pediatric endocrinologists -\nDEER PARK, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that it has entered into a multi-year agreement with Tolmar Pharmaceuticals, Inc. to co-promote ALKINDI SPRINKLE®. Eton will leverage Tolmar’s 62-person sales force and their existing relationships in the pediatric endocrinology specialty. Tolmar currently promotes FENSOLVI® (leuprolide acetate) for injectable suspension, indicated for pediatric patients 2 years of age and older with Central Precocious Puberty (CPP). “It’s clear that physicians see the need for ALKINDI SPRINKLE’s accurate dosing when treating adrenal insufficiency, however, we have found that changing the decades old prescribing habits of pediatric endocrinologists is often requiring multiple face-to-face interactions. With this partnership, our reach will be increasing more than 10-fold and we will drastically increase the number of face-to-face interactions. We believe this will translate to significantly faster adoption of ALKINDI SPRINKLE and accelerate the time to reach peak conversion,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “We are confident Tolmar is the right partner for ALKINDI SPRINKLE. Their FENSOLVI® launch results speak for themselves and highlight their team’s ability to drive treatment change in pediatric endocrinology,” added Brynjelsen. “We are excited to co-promote ALKINDI SPRINKLE,” said Tolmar CEO Anil D’Souza. “This agreement will further enhance Tolmar’s commitment to the pediatric endocrinology space. It allows Tolmar to continue providing therapies with optimal delivery mechanisms that improve patient and caregiver experience.” Tolmar’s pediatric endocrinology sales force currently promotes the specialty drug FENSOLVI® for CPP, a rare disease that impacts roughly one in 5,000-10,000 children in the United States. FENSOLVI® was launched in May 2020 and has already reached more than 1,500 patients. Under terms of the agreement, Tolmar’s sales force will promote ALKINDI SPRINKLE® to their pediatric endocrinology targets alongside FENSOLVI®. Tolmar will receive a royalty on net sales growth above ALKINDI SPRINKLE®’s current baseline sales. Eton’s sales force will continue to promote the product and Eton will maintain responsi...